Clinical Trials Logo

HER-2 Protein Overexpression clinical trials

View clinical trials related to HER-2 Protein Overexpression.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03680560 Terminated - Solid Tumor Clinical Trials

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Start date: March 13, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, multi-center study to assess safety and determine the recommended phase 2 dose (RP2D) of ACTR T cell product (ACTR707 or ACTR087) in combination with trastuzumab, following lymphodepleting chemotherapy in subjects with HER2-positive advanced malignancies.

NCT ID: NCT03630809 Terminated - Breast Cancer Clinical Trials

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

Start date: January 10, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to learn more about how to treat patients with a diagnosis of diagnosis of Human Epidermal Growth Factor Receptor 2/neu (HER-2/neu) positive breast cancer in the past, who were previously treated with HER-2/neu-directed dendritic cells (DC) vaccines. There is evidence that the use of anti-HER2 dendritic cell (DC) study vaccines could improve response to breast cancer therapy and be an important step in the prevention of recurrence. This study will use a Dendritic Cell Type 1 (DC1) vaccine which is a HER2-sensitized dendritic cell (DC) study vaccine. Dendritic cells are immune cells that can tell the participant's immune system to fight infection. This study vaccine will be made from the participant's blood cells collected from a procedure called leukapheresis.

NCT ID: NCT02840110 Terminated - Multiple Myeloma Clinical Trials

Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product

Start date: October 2016
Phase:
Study type: Observational

Subjects treated with an ACTR product may participate in this long-term follow-up study after the completion of the final scheduled visit in the parent clinical study or other investigational setting, such as compassionate use, named patient Investigational New Drug application, expanded access program, or equivalent setting. No investigational product or treatment will be administered in this study. These subjects will be followed for safety monitoring on a schedule of decreasing frequency through 15 years post-ACTR treatment, in accordance with US FDA Regulatory guidance pertaining to long-term safety follow-up for study subjects receiving recombinant DNA-containing investigational products.